Lasmiditan Succinate

Thomas P. Mathers Anaveon appoints Thomas P. Mathers as Chair of the Board of Directors. BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Thomas P. Mathers as Chair of its Board of Directors. His appointment will be confirmed in the upcoming Annual General Meeting in June. Dieter Weinand, who served as Chair since 2024, has stepped down from the Board. Mr. Mathers brings over 32 years of distinguished executive leadership in the life sciences sector, with a proven track record in company building, capital raising, public market transitions, and strategic value creation. As a Partner at Pappas Capital and Executive Chairman of Aer Therapeutics, he is widely recognized for his expertise in advancing innovative therapies from discovery through commercialization. “We are thrilled to welcome Tom as Chair of Anaveon’s Board at this pivotal moment,” said Thaminda Ramanayake, Chief Executive Officer of Anaveon . “His exceptional experience in scaling biotechnology companies, securing substantial financing, and navigating complex regulatory and commercial landscapes will be invaluable as we advance our lead immunology programs into clinical development and expand our pipeline of novel drug candidates. We are deeply grateful to Dieter Weinand for his dedicated service and strategic guidance during a critical foundational period and wish him continued success.” “I am honored to join Anaveon as Chair of the Board,” said Thomas P. Mathers. “The company’s innovative approach to selectively modulating immune pathways has tremendous potential to deliver transformative therapies for patients with significant unmet needs in autoimmune diseases. I look forward to partnering with Thaminda, the executive team, and the Board to accelerate growth, strengthen strategic execution, and realize Anaveon’s vision of reshaping immune-mediated disease treatment.” Leadership in Action: Thomas P. Mathers’ Track Record Mr. Mathers currently serves as Executive Chairman (and Interim CEO) of Aer Therapeutics, developing novel therapies for serious airway diseases, and as Vice Chairman of Certa Therapeutics, focused on fibrosis treatments. He is also Treasurer and a member of the Executive Committee of the Biotechnology Innovation Organization (BIO), where he actively shapes advocacy, regulatory policy, capital formation, bioethics, and intellectual property initiatives. He additionally serves on the U.S. Department of Veterans Affairs Research Advisory Committee on Gulf War Veterans’ Illnesses. In 2019, he founded Allievex Corp., a clinical-stage company developing therapies for neuronopathic lysosomal storage diseases such as Sanfilippo Syndrome. He led the company as President, CEO, and Director until its acquisition by Spruce Biosciences in 2024. Previously, as President and CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD), he advanced lasmiditan for acute migraine treatment through key development milestones, culminating in its acquisition by Eli Lilly in 2017 for nearly $1 billion. Earlier in his career, Mr. Mathers held senior leadership roles at Peptimmune, Cell Based Delivery, Cardion AG, and Genzyme Corporation. He holds a B.S. in Engineering from the United States Military Academy at West Point (1988), where he played varsity football. He served as a Captain and AH-64 Apache helicopter pilot in the U.S. Army during the Gulf War, earning multiple military honors. ENDS Media contact: Benz Advisory Beatrix Benz Email: beatrix.benz@anaveon.com Tel: +41 79 256 77 73 About Anaveon: Anaveon AG is a late-stage preclinical biotechnology company headquartered in Basel, Switzerland focused on developing next-generation precision biologics that target central regulatory nodes of the immune system. The company’s engineered antibodies and cytokine-based therapies aim to selectively eliminate or reprogram pathogenic immune cells, restoring durable immune balance in autoimmune and inflammatory diseases. For more information, visit > anaveon.com A photo accompanying this announcement is available at

2026.3.31 2026年3月31日，CDE官网显示辉瑞“硫酸瑞美吉泮口崩片”新增成人阵发性偏头痛预防适应症的上市申请获受理。 图片来源：CDE官网 而这款全球首个兼具急性与预防双适应症的CGRP受体拮抗剂口崩片，正推动偏头痛治疗从传统对症干预向精准靶向预防跨越。 偏头痛治疗变革：从对症缓解到精准靶向 对于偏头痛的治疗，其自古以来均主要以缓解症状为主要目标，后来随着基础研究水平的上涨，血管假说出现，彼时采用麦角胺类血管收缩剂用以缓解症状，但副作用显著，限制了长期使用。 20世纪90年代，曲坦类药物（如舒马曲坦）问世，通过抑制CGRP释放中止发作，成为急性治疗的重要突破，却因存在血管收缩作用，在合并冠心病、高血压等症状的患者群体中被提示慎用，且无法从根源预防发作。而同期预防性用药多为“再利用药物”，如β受体阻滞剂、抗癫痫药、三环类抗抑郁药，虽有一定疗效，但特异性差、副作用明显，患者依从性低。 直至2020年前后，CGRP通路靶向药物的获批成为偏头痛治疗的里程碑，其意义在于从传统“对症”到“对因”的跨越。这类药物通过阻断CGRP神经肽或其受体，精准干预偏头痛核心病理机制，无血管收缩作用，安全性更优。 针对CGRP通路靶向药物领域，目前已逐渐演变出两种不同的技术类型： 一者是CGRP单抗类，其通过靶向结合CGRP受体或配体，从而阻断偏头痛相关的信号传递，可显著减少每月偏头痛天数，并改善患者生活质量，2024年美国头痛学会（AHS）将靶向CGRP信号通路药物列为偏头痛预防性治疗的一线选择。比如诺华依瑞奈尤单抗、礼来加卡奈珠单抗等。 二者是口服CGRP受体拮抗剂，即熟知的吉泮类药物，其较生物制剂最大的区别在于口服便捷，可适配更多患者场景，其中“瑞美吉泮”凭借口崩片剂型，无需饮水即可服用，临床数据显示，可在45分钟内缓解疼痛，60分钟恢复正常功能，疗效持续可达48小时，且兼具急性与预防双适应症，已被中美欧偏头痛指南强推荐。 而随着CGRP靶向药在偏头痛领域的成功，研究层面也开始逐步出现其他靶向药方向，比如，5-HT1F激动剂（如拉米地坦）为心血管高危患者提供无血管收缩风险的选择；双特异性抗体、小核酸药物等新型疗法处于临床阶段，有望覆盖更多难治性患者亚型。 CGRP靶点竞争格局：国内三强领跑，全球管线密集 针对瑞美吉泮所在的CGRP靶向药赛道，截至目前，全球范围已有8款CGRP/CGRP受体靶向药物获批上市，中国获批3款，形成“口服 + 注射”的差异化竞争格局。 数据来源：药智数据（如有错误请指正，点击查看大） 新药在研方面，赛道领域临床阶段管线并不算多，除默沙东、格林格殷格翰等MNC药企之外，国内君实生物等企业的吉泮类药物处于临床前或 I 期阶段，聚焦口服与注射剂型，瞄准本土化需求。 数据来源：药智数据（如有错误请指正，点击查看大图） 小结 总而言之，辉瑞瑞美吉泮预防偏头痛适应症的申报上市，虽非偏头痛治疗正式进入 “精准预防”时代的起始信号。但也是赛道竞争逐步激烈的开始阶段。 而随着CGRP靶点药物的普及与剂型创新，尤其是国产药企在该领域的快速成长，“跨国药企领跑 + 本土企业追赶”的格局也将被彻底打开，推动治疗方案进一步优化，惠及更多患者。 参考资料 1.辉瑞官网信息 2.《中国偏头痛诊断与治疗指南（中华医学会神经病学分会第一版）》 3.《2025年神经病学指南与共识》 扫描二维码 更多行业前沿分享 博腾股份成立于2005年，主要为全球药企、生物科技公司、科研机构等提供从临床前研究到药品上市全生命周期所需的小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物等一站式服务解决方案，研发、生产、运营场地覆盖中国（重庆、上海、四川、江苏、江西、湖北）、美国、斯洛文尼亚、比利时、瑞士和丹麦等地。我们始终坚持以客户为中心，致力于为客户提供创新、可靠的全球化、端到端CDMO服务，让好药更早惠及大众。 免责声明：文中系整合内容，观点不代表博腾及其所属子公司立场，亦不对本文所提供信息做任何形式的保证。同时，本文不做治疗方案推荐，也不承担因使用或依赖本文信息所产生的任何直接或间接的后果。如需获得治疗方案指导，请前往正规医院就诊。